Aethlon Medical (NASDAQ:AEMD – Get Rating) will release its earnings data after the market closes on Wednesday, June 28th. Analysts expect Aethlon Medical to post earnings of ($0.16) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.
Aethlon Medical Stock Performance
Shares of AEMD stock opened at $0.38 on Monday. Aethlon Medical has a one year low of $0.23 and a one year high of $2.46. The company has a 50 day moving average price of $0.36 and a 200 day moving average price of $0.40. The firm has a market capitalization of $8.73 million, a price-to-earnings ratio of -0.51 and a beta of 1.18.
Hedge Funds Weigh In On Aethlon Medical
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP grew its holdings in Aethlon Medical by 219.3% during the first quarter. Two Sigma Investments LP now owns 127,341 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 87,458 shares during the last quarter. Jane Street Group LLC grew its holdings in Aethlon Medical by 895.7% during the fourth quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 126,160 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Aethlon Medical by 61.4% during the fourth quarter. Renaissance Technologies LLC now owns 100,600 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 38,264 shares during the last quarter. HRT Financial LP acquired a new position in Aethlon Medical during the fourth quarter valued at approximately $28,000. Finally, Vanguard Group Inc. grew its holdings in Aethlon Medical by 112.9% during the third quarter. Vanguard Group Inc. now owns 1,053,198 shares of the medical equipment provider’s stock valued at $613,000 after purchasing an additional 558,596 shares during the last quarter. Institutional investors own 4.44% of the company’s stock.
Analyst Ratings Changes
About Aethlon Medical
Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes.
Read More
- Get a free research report on Aethlon Medical from StockNews.com
- MarketBeat Week in Review – 6/19 – 6/23
- CarMax Stock Flying On Earnings Beat, Return Of The Highs?
- Commercial Metals Company Shakes Off The Rust: Confirms Uptrend
- Smith & Wesson, A Timeless Value Play At Decade Lows
- Five stocks we like better than Aethlon Medical
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
